Follow‐up of sentinel node negative breast cancer patients without axillary lymph node dissection

Schrenk, Peter; Hatzl-Griesenhofer, M; Shamiyeh, Andreas; Waynad, Wolfgang

doi:10.1002/jso.1089

Cited by 95 publications

(40 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eleven previous studies have shown that axillary lymph node recurrence in early-stage breast carcinoma is rare after SLND alone, ranging from 0% to 1.4% at 22-46 months after surgery (Table 3). 4,[7][8][9][10][11][12][13][14][15] The current study of nearly 700 patients provides additional evidence that axillary lymph node recurrences occur infrequently after SLND alone (Ͻ 1%), and all 4 of the axillary lymph node recurrences in the current study were amenable to further treatment. In SLND studies, including the current study, the axillary lymph node recurrence rate after SLND is comparable to or less than the axillary lymph node recurrence rate of 1-2.5% after ALND for early-stage breast carcinoma at a median interval of 2.6 years between axillary surgery and disease recurrence.…”

Section: Discussionmentioning

confidence: 54%

“…2,5 Furthermore, the side effects of SLND are negligible compared with the side effects of ALND. [3][4][5][7][8][9] However, the greatest concern with conducting SLND alone is the occurrence of a false-negative SLN biopsy. As a result, effective adjuvant therapy may not be offered and axillary metastases would be left untreated in the axilla, thus increasing the potential for axillary lymph node recurrence.…”

mentioning

confidence: 99%

“…Several studies have shown that axillary lymph node recurrences are rare after negative SLND alone in patients with early-stage breast carcinoma. 4,[7][8][9][10][11][12][13] Even studies that include patients with positive lymph nodes after SLND and no further axillary dissection showed a very low disease recurrence rate. [13][14][15] However, further studies are needed to provide additional data on the safety and efficacy of SLND for patients with early-stage breast carcinoma, especially with longer-term follow-up.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma

Swenson

Mahipal

Nissen

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDSurgical recommendation for early‐stage breast carcinoma includes removal of the primary breast tumor and evaluation of the axillary lymph nodes on the ipsilateral side. Sentinel lymph node dissection (SLND) is increasingly being used to evaluate axillary lymph nodes in clinically lymph node negative patients as an alternative to axillary lymph node dissection (ALND). Results from SLND are highly predictive of metastatic involvement in the axilla, and are associated with fewer side effects. However, the greatest concern with SLND alone is the potential for a higher rate of axillary lymph node recurrence. The purpose of the current study was to review data collected on 700 consecutive patients with early‐stage breast carcinoma who underwent SLND without concomitant ALND.METHODSA retrospective study was conducted using the oncology registry at Park Nicollet Health Services (Minneapolis, MN). Consecutive breast carcinoma cases with SLND only for axillary surgery, from January 28, 1999 to December 31, 2003, were included in the study. During this period, 700 patients with breast carcinoma were identified who had SLND alone. Fifty‐two patients were excluded from the analysis because they had ductal carcinoma in situ.RESULTSWith a median follow‐up of 33 months (range, 2‐73 mos), axillary lymph node recurrence occurred in 4 of 647 (0.62%) patients overall. In these 4 patients, the axillary lymph node recurrences were isolated to the axillary lymph nodes and amenable to surgery.CONCLUSIONSData from the current study showed that axillary lymph node recurrence after SLND occurred very infrequently in early‐stage breast carcinoma, and these results were comparable to other studies. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 54%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma

Swenson

Mahipal

Nissen

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…The long-term outcome of SLNB without ALND has not yet been evaluated and prospective randomised trials comparing SLNB alone vs SLNB plus ALND in SLN-negative patients as the American NSABP-B 32 trial or the European ALMANAC trial are in the recruitment phase. Few data exist on the local control of SLNB and there are only a few reports on SLNB alone without further ALND to date (Giuliano et al, 2000;Roumen et al, 2001;Schrenk et al, 2001;Chung et al, 2002). Axillary recurrences, as reported in those studies, range between 0 and 1.4% and follow-up periods range between 22 and 39 months.…”

Section: Discussionmentioning

confidence: 97%

200 Sentinel lymph node biopsies without axillary lymph node dissection – no axillary recurrences after a 3-year follow-up

Reitsamer

Peintinger²,

Prokop

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

The aim of this study is to evaluate the rate of axillary recurrences in sentinel lymph node (SLN)-negative breast cancer patients after sentinel lymph node biopsy (SLNB) alone without further axillary lymph node dissection (ALND). Between May 1999 and February 2002, 333 consecutive patients with primary invasive breast cancer up to 4 cm and clinically negative axillae were entered into this prospective study. Sentinel lymph nodes were identified using the combined method with blue dye (Patent blue V s ) and technetium 99m-labelled albumin (Nanocoll s ). Sentinel lymph nodes were examined by frozen sections, standard haematoxylin and eosin staining and immunohistochemistry staining. In SLN-positive patients, ALND was performed. Sentinel lymph node-negative patients had no further ALND. The SLN identification rate was 98.5% (328 out of 333). In all, 128 out of 328 (39.0%) patients had positive SLNs and complete ALND. A total of 200 out of 328 (61.0%) patients were SLN negative and had no further ALND. The mean tumour size of SLN-negative patients was 16.5 mm. The mean number of SLNs removed was 2.1 per patient. There were no local or axillary recurrences at a median follow-up of 36 months. The absence of axillary recurrences after SLNB without ALND in SLNnegative breast cancer patients supports the hypothesis that SLNB is accurate and safe while providing less surgical morbidity than ALND. Short-term results are very promising that SLNB without ALND in SLN-negative patients is an excellent procedure for axillary staging in a cohort of breast cancer patients with small tumours.

show abstract

“…Also, no lymphedema, insensibility, or decreased arm mobility (function) were noted. One case of seroma formation and 1 case of wound infection were also detected during follow up (8).…”

Section: Discussionmentioning

confidence: 93%

Axillary Recurrence Rate in Patients with Breast Cancer and Negative Sentinel Lymph Node Biopsy

et al. 2017

View full text Add to dashboard Cite

Background: Sentinel lymph node biopsy is the standard method of evaluating and staging the axilla in the patients with early stage of the breast cancer. The aim of this study is to evaluate the axillary recurrence rate in patients with negative sentinel node biopsy. Methods: From 2006 to 2010, all the patients with a negative sentinel lymph node in their pathologic results were introduced in the study. All patients were invited to the breast cancer clinic for the follow up examination. The axillary ultrasonography was performed to determine the recurrence. Results: Among 150 female patients with negative sentinel lymph node, 52 were entered into the study and were followed up. The

show abstract

Follow‐up of sentinel node negative breast cancer patients without axillary lymph node dissection

Abstract: Although the follow-up is very short, SN biopsy only in node-negative breast cancer patients had no negative impact on the axillary failure rate and resulted in negligible morbidity.

Cited by 95 publications

References 36 publications

Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma

Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma

200 Sentinel lymph node biopsies without axillary lymph node dissection – no axillary recurrences after a 3-year follow-up

Axillary Recurrence Rate in Patients with Breast Cancer and Negative Sentinel Lymph Node Biopsy

Contact Info

Product

Resources

About